Current status of anti-EGFR agents

Epidermal growth factor receptor (EGFR) is one of the most essential and attractive clinical and scientific attention targets in most cancer therapies. It is involved in the pathogenesis and metastasis of related cancers, showing a decisive modulatory role in these pathways. Clinical trials have demonstrated that monoclonal antibodies and tyrosine kinase inhibitors can benefit and receive drug approval by targeting this receptor in cancer therapy. However, therapeutic strategies are minimal and have broad room for improvement. This chapter reviews the current mainstream cancer treatment options and related studies targeting EGFR in cancer therapy. With a brief introduction to the role of EGFR in cancer and cancer therapy, this chapter provides a comprehensive list of EGFR-targeted cancer therapy drugs. Among them, some drugs are approved for clinical use, and some drugs are in preclinical research or have failed to enter clinical use for related reasons. Finally, this chapter discusses newly developed preclinical stage novel anti-EGFR cancer therapies and drugs.